132 related articles for article (PubMed ID: 25605819)
21. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
[TBL] [Abstract][Full Text] [Related]
22. Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta.
Pridham KJ; Hutchings KR; Beck P; Liu M; Xu E; Saechin E; Bui V; Patel C; Solis J; Huang L; Tegge A; Kelly DF; Sheng Z
iScience; 2024 Jun; 27(6):109921. PubMed ID: 38812542
[TBL] [Abstract][Full Text] [Related]
23. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets.
Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD
Cells; 2024 Feb; 13(5):. PubMed ID: 38474373
[TBL] [Abstract][Full Text] [Related]
24. Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review).
Yashin KS; Yuzhakova DV; Sachkova DA; Kukhnina LS; Kharitonova TM; Zolotova AS; Medyanik IA; Shirmanova MV
Sovrem Tekhnologii Med; 2023; 15(3):61-71. PubMed ID: 38435477
[TBL] [Abstract][Full Text] [Related]
25. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
Shan KS; Bonano-Rios A; Theik NWY; Hussein A; Blaya M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396649
[TBL] [Abstract][Full Text] [Related]
26. Biomimetic Synthesis and Chemical Proteomics Reveal the Mechanism of Action and Functional Targets of Phloroglucinol Meroterpenoids.
Bracken AK; Gekko CE; Suss NO; Lueders EE; Cui Q; Fu Q; Lui ACW; Anderson ET; Zhang S; Abbasov ME
J Am Chem Soc; 2024 Jan; 146(4):2524-2548. PubMed ID: 38230968
[TBL] [Abstract][Full Text] [Related]
27. The Glioblastoma Landscape: Hallmarks of Disease, Therapeutic Resistance, and Treatment Opportunities.
Boylan J; Byers E; Kelly DF
Med Res Arch; 2023 Jun; 11(6):. PubMed ID: 38107346
[TBL] [Abstract][Full Text] [Related]
28. From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
Dewdney B; Jenkins MR; Best SA; Freytag S; Prasad K; Holst J; Endersby R; Johns TG
Signal Transduct Target Ther; 2023 Oct; 8(1):400. PubMed ID: 37857607
[TBL] [Abstract][Full Text] [Related]
29. Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers.
Rabah N; Ait Mohand FE; Kravchenko-Balasha N
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762559
[TBL] [Abstract][Full Text] [Related]
30. Fungal Drug Discovery for Chronic Disease: History, New Discoveries and New Approaches.
Prescott TAK; Hill R; Mas-Claret E; Gaya E; Burns E
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371566
[TBL] [Abstract][Full Text] [Related]
31. Orellanine: From Fungal Origin to a Potential Future Cancer Treatment.
Lyons MJ; Ehrhardt C; Walsh JJ
J Nat Prod; 2023 Jun; 86(6):1620-1631. PubMed ID: 37308446
[TBL] [Abstract][Full Text] [Related]
32. Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis.
Sun MY; Bhaskar SMM
Diagnostics (Basel); 2022 Nov; 12(12):. PubMed ID: 36552961
[TBL] [Abstract][Full Text] [Related]
33. The Next Frontier in Health Disparities-A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back.
Diaz Rosario M; Kaur H; Tasci E; Shankavaram U; Sproull M; Zhuge Y; Camphausen K; Krauze A
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139042
[TBL] [Abstract][Full Text] [Related]
34. Multi-Targeting Approach in Glioblastoma Using Computer-Assisted Drug Discovery Tools to Overcome the Blood-Brain Barrier and Target EGFR/PI3Kp110β Signaling.
Franco C; Kausar S; Silva MFB; Guedes RC; Falcao AO; Brito MA
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884571
[TBL] [Abstract][Full Text] [Related]
35. ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair.
Jiao W; Zhu S; Shao J; Zhang X; Xu Y; Zhang Y; Wang R; Zhong Y; Kong D
Biomed Res Int; 2022; 2022():8568528. PubMed ID: 35872860
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds.
Liu H; Qiu W; Sun T; Wang L; Du C; Hu Y; Liu W; Feng F; Chen Y; Sun H
Acta Pharm Sin B; 2022 Apr; 12(4):1781-1804. PubMed ID: 35847506
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Options in Neuro-Oncology.
Afonso M; Brito MA
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628161
[TBL] [Abstract][Full Text] [Related]
38. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng Y; Wang Y; Zhou C; Mei W; Zeng C
Front Oncol; 2022; 12():819128. PubMed ID: 35402264
[TBL] [Abstract][Full Text] [Related]
39. Molecular Mechanisms and Clinical Challenges of Glioma Invasion.
Oishi T; Koizumi S; Kurozumi K
Brain Sci; 2022 Feb; 12(2):. PubMed ID: 35204054
[TBL] [Abstract][Full Text] [Related]
40. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma.
Barzegar Behrooz A; Talaie Z; Jusheghani F; Łos MJ; Klonisch T; Ghavami S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
